Pages that link to "Q42502209"
Jump to navigation
Jump to search
The following pages link to BRCA1 dysfunction in sporadic basal-like breast cancer (Q42502209):
Displaying 50 items.
- Transcriptional regulation of BRCA1 expression by a metabolic switch (Q24307973) (← links)
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (Q24644255) (← links)
- Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer (Q24652213) (← links)
- Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer (Q24654216) (← links)
- ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer (Q26740452) (← links)
- Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes (Q26743510) (← links)
- Targeting triple-negative breast cancer: optimising therapeutic outcomes (Q26850892) (← links)
- Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery (Q26851813) (← links)
- Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers (Q27006938) (← links)
- The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations (Q27026264) (← links)
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies (Q27027503) (← links)
- Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer (Q28372484) (← links)
- The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis (Q28388257) (← links)
- Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy (Q28535227) (← links)
- Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers (Q28542563) (← links)
- PARP Inhibitor Treatment in Ovarian and Breast Cancer (Q28741688) (← links)
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer (Q29619481) (← links)
- Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications (Q30245184) (← links)
- MicroRNA in breast cancer: The association with BRCA1/2. (Q33364654) (← links)
- The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer (Q33378965) (← links)
- Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers (Q33379276) (← links)
- The UPS: a promising target for breast cancer treatment. (Q33384289) (← links)
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer (Q33393514) (← links)
- A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes (Q33426722) (← links)
- Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer (Q33539418) (← links)
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer (Q33565650) (← links)
- Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis (Q33570282) (← links)
- A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors (Q33578636) (← links)
- Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays (Q33607569) (← links)
- Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer (Q33646285) (← links)
- Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. (Q33649918) (← links)
- β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast (Q33652448) (← links)
- Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer (Q33669053) (← links)
- Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. (Q33722847) (← links)
- Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers (Q33748161) (← links)
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease (Q33769821) (← links)
- HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. (Q33815755) (← links)
- DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response (Q33816178) (← links)
- Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin (Q33839776) (← links)
- Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers (Q33863531) (← links)
- Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry (Q33864102) (← links)
- Transcriptional regulation of the base excision repair pathway by BRCA1 (Q33911232) (← links)
- Genomic instability in breast cancer: pathogenesis and clinical implications (Q33998514) (← links)
- Regulation of the BRCA1 gene by an SRC3/53BP1 complex (Q34018414) (← links)
- Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer (Q34018681) (← links)
- Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner (Q34109373) (← links)
- Deconstructing the molecular portraits of breast cancer (Q34154147) (← links)
- miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors (Q34157084) (← links)
- Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer (Q34168535) (← links)
- Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. (Q34176503) (← links)